
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): February 20, 2018

MYLAN N.V.
(Exact Name of Registrant as Specified in its Charter)

The Netherlands
(State or Other Jurisdiction
of Incorporation)

333-199861
(Commission
File Number)

98-1189497
(I.R.S. Employer
Identification No.)

Building 4, Trident Place Mosquito Way, Hatfield, Hertfordshire
(Address of Principal Executive Offices)

AL10 9UL
(Zip Code)

Registrant's telephone number, including area code: +44 (0) 1707-853-000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 20, 2018, Ms. Wendy Cameron, a director of Mylan N.V. (the “Company”) notified the Company that she will retire from the Company’s Board of Directors (the “Board”) effective as of the end of her term at the Company’s Annual General Meeting of Shareholders (the “Annual Meeting”). Ms. Cameron has served on the Board for more than 16 years, including service as Chair of the Compensation Committee and on the Governance & Nominating Committee and other committees.

The Company issued a press release regarding Ms. Cameron’s retirement and the nomination of Ms. Pauline van der Meer Mohr as a candidate for election to the Board at the Annual Meeting which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit No. | Description |
|----------------|---|
| 99.1 | Press Release dated February 26, 2018 |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MYLAN N.V.

Date: February 26, 2018

By: /s/ Kenneth S. Parks
Kenneth S. Parks
Chief Financial Officer

FOR IMMEDIATE RELEASE

CONTACTS:
Christine Dusek (Media)
724.514.1968

Melissa Trombetta (Investors)
724.514.1813

16-Year Veteran Director Wendy Cameron to Retire from Mylan N.V. Board after 2018 AGM

Mylan Board Nominates Pauline van der Meer Mohr for Election to Board of Directors

HERTFORDSHIRE, England and PITTSBURGH, February 26, 2018 /PRNewswire/ — The Mylan N.V. (NASDAQ: MYL) Board of Directors today announced that non-executive Director Wendy Cameron will retire from the Board after more than 16 years of service, effective after the 2018 Annual General Meeting of Shareholders. The Board also announced that it has nominated Pauline van der Meer Mohr as a candidate for election to Mylan's Board at the 2018 Annual General Meeting.

Mylan Chairman Robert J. Coury stated, "On behalf of Mylan's Board of Directors, I want to express my deepest appreciation for Wendy's more than 16 years of outstanding service to the Board and to all of Mylan's stakeholders, including her service as Chair of the Compensation Committee and her previous service on the Governance & Nominating and other committees. Wendy's leadership and significant contributions to the Board have been instrumental in helping guide Mylan's strategic development, growth, and global transformation."

Mr. Coury continued, "The Mylan Board has continued to refresh itself over the past decade as the Company has evolved into a leading global healthcare company, adding seven of its current eleven directors during that time frame, including four in the past five years. As the Company continues to evolve and continues the natural refreshment of its Board, we believe that Pauline represents yet another outstanding addition to the Board, given her extensive experience as a director of several multi-national companies operating in a broad range of industries, as well as her expertise in, among other areas, executive compensation, risk oversight, governance, regulatory and audit-related matters, sustainability, and talent development. I am confident that the Board and Mylan's stakeholders will greatly benefit from her expertise, practical judgment, and fresh perspectives."

Ms. van der Meer Mohr is a highly respected and influential corporate leader and has significant global and Dutch company board experience. She currently is a non-executive director of HSBC Holdings plc, chairing that company's Group Remuneration (compensation) Committee and Conduct & Values Committee, and serving on its Nomination Committee. She also is a member of the supervisory boards of Royal DSM NV (currently chairing that company's Remuneration Committee and serving on its Nomination Committee), ASML Holding NV (currently serving on the Audit Committee and Selection & Nomination Committee), and EY Netherlands LLP (currently serving as Chair). In addition, she recently served as President of the Executive Board of Erasmus University in Rotterdam. Ms. van der Meer Mohr began her career in the legal profession and previously held several legal and management positions within Royal Dutch Shell Group from 1989-2004. In 2004, she was appointed group human resources director at TNT NV before becoming senior executive vice president and head of group human resources at ABN AMRO NV in 2006. She served as a member of the Dutch Banking Code Monitoring Commission in the Netherlands from 2010 to 2013, and began her own human capital consulting firm in 2008.

Ms. van der Meer Mohr said, “I am honored to have been nominated for election to the Mylan N.V. Board. I have spent a great deal of time learning about the Company and meeting with the Board members and management team, and I am truly impressed by the Company’s remarkable growth and success in developing such a robust and diverse global platform over a short period of time, as well as its passionate commitment to delivering on the Company’s bold mission statement. I believe that Mylan has deservedly achieved its reputation as a respected leader in the global pharmaceutical industry. I am excited to have the opportunity, if elected, to use my experience to work with Mylan’s outstanding, dynamic Board and management team as the Company faces the challenges of an increasingly complex and changing healthcare environment and seeks to maximize opportunities for shareholders and all other stakeholders.”

About Mylan

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what’s right, not what’s easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world’s largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at [Mylan.com](https://www.mylan.com). We routinely post information that may be important to investors on our website at investor.mylan.com.

###